3rd Webinar on
COVID-19 Vaccines
August 27, 2021
Scientific Program
Keynote Session:
Title: Evidence for and level of herd immunity against SARS-CoV-2 infection: the ten-community study
Biography:
Andrew Jeremijenko did his medical education in Queensland. He is both a GP and a specialist in Occupational and Environmental Medicine. He has also completed:Masters of Applied Epidemiology MAE, Certificate of Higher Education (Adult education), Masters of Health Administration MHA. Andrew has worked in Australia and overseas as:Chief Medical Officer Woodside, BP Medical Advisor, Indonesia, Coordinating Doctor, International SOS Jakarta, RFDS Port Hedland medical officer. Andrew has dealt with bomb victims, tsunami and earthquake victims and industrial accidents and explosions in Indonesia.
Abstract:
Background Qatar experienced a large severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic that disproportionately affected the craft and manual workers (CMWs) who constitute 60% of the population. This study aimed to investigate level of immunity in communities within this population as well as infection exposure required to achieve herd immunity. Methods Anti-SARS-CoV-2 seropositivity was assessed in ten CMW communities between June 21 and September 9, 2020. PCR positivity, infection positivity (antibody and/or PCR positive), and infection severity rate were also estimated. Associations with anti-SARS-CoV-2 positivity were investigated using regression analyses.
Title: The Ideal SARS-CoV-2 Vaccine
Biography:
Scott conducted a Postdoctoral Fellowship at the Moffitt Cancer Center and was subsequently accepted into the highly competitive FDA Commissioner’s Fellowship Program where he worked in the Office of Orphan Products Development (OOPD) and published a paper in Cell Stem Cell. During the Fellowship, Scott was hired into OOPD at the FDA where he remained until relocation to the Boston area. After relocation, Scott has served various roles in regulatory affairs, intelligence, and research in both consulting and the biopharmaceutical industry. He has multiple peer-reviewed publications including a book chapter on orphan drug development in FDA Regulatory Affairs, 3rd Ed. His interest in SARS-CoV-2 was piqued upon reconnecting with a friend who is an immunologist from his days as a Postdoctoral Fellow who he has co-authored a manuscript with entitled “A new vaccine approach and convalescent plasma until its development.”
Abstract:
It is of concern that major vaccine developers are targeting spike (S) the most mutation-prone region of SARS-CoV-2. By the end of April 2020, at least 14 circulating mutations had been identified, with all of them occurring in S. Variants of Concern (VOC) including B.1.1.7 (United Kingdom), B.1.351 (South Africa), P.1 (Brazil), and B.1.617 (India) have concurrently arisen during vaccine development and roll out. While some may affect infectivity, preliminary evidence suggests that some may affect vaccine efficacy as the VOCs involve mutations within S. Indeed, there is already work being conducted on so-called “boosters” to provide additional immunization to these variants. It is of great concern that a VOC with a high level of resistance to vaccination-induced immunity will arise before a “booster” can be developed and distributed to counter it. It is felt that the only logical way to solve the SARS-CoV-2 problem via vaccination without risking an escape mutation is via a multiepitope approach. Sera from recovered patients demonstrates that there are other logical targets to utilize. Bioinformatics approaches have predicted B- and T-cell epitopes of interest and suggest potential concomitant sequences for vaccination targets. A comparison of sequences yielded by bioinformatics approaches and those occurring in recovered patients can help in finding the correct targets.
Title: The Ideal SARS-CoV-2 Vaccine
Biography:
Scott conducted a Postdoctoral Fellowship at the Moffitt Cancer Center and was subsequently accepted into the highly competitive FDA Commissioner’s Fellowship Program where he worked in the Office of Orphan Products Development (OOPD) and published a paper in Cell Stem Cell. During the Fellowship, Scott was hired into OOPD at the FDA where he remained until relocation to the Boston area. After relocation, Scott has served various roles in regulatory affairs, intelligence, and research in both consulting and the biopharmaceutical industry. He has multiple peer-reviewed publications including a book chapter on orphan drug development in FDA Regulatory Affairs, 3rd Ed. His interest in SARS-CoV-2 was piqued upon reconnecting with a friend who is an immunologist from his days as a Postdoctoral Fellow who he has co-authored a manuscript with entitled “A new vaccine approach and convalescent plasma until its development.â€
Abstract:
It is of concern that major vaccine developers are targeting spike (S)—the most mutation-prone region of SARS-CoV-2. By the end of April 2020, at least 14 circulating mutations had been identified, with all of them occurring in S. Variants of Concern (VOC) including B.1.1.7 (United Kingdom), B.1.351 (South Africa), P.1 (Brazil), and B.1.617 (India) have concurrently arisen during vaccine development and roll out. While some may affect infectivity, preliminary evidence suggests that some may affect vaccine efficacy as the VOCs involve mutations within S. Indeed, there is already work being conducted on so-called “boosters†to provide additional immunization to these variants. It is of great concern that a VOC with a high level of resistance to vaccination-induced immunity will arise before a “booster†can be developed and distributed to counter it. It is felt that the only logical way to solve the SARS-CoV-2 problem via vaccination without risking an escape mutation is via a multiepitope approach. Sera from recovered patients demonstrates that there are other logical targets to utilize. Bioinformatics approaches have predicted B- and T-cell epitopes of interest and suggest potential concomitant sequences for vaccination targets. A comparison of sequences yielded by bioinformatics approaches and those occurring in recovered patients can help in finding the correct targets
Oral Session 1:
- COVID Vaccines | Vaccine Distribution| Veterinary Vaccinology
Title: BENEFITS IN THE NEWBORNS IMMUNE SYSTEM WHEN SUPPLEMENTING WITH VITAMIN D3 AND ZINC
Biography:
Dr. Maria Bertha Romo Almanza, completed her postgraduate degree in Neonatology at the National Institute of Perinatology, in Mexico City, completing this specialty at 30 years edge (2009), previously she has a specialty in Pediatrics at the Children's Hospital in Saltillo Coahuila, currently she is Chief in charge in Neonatology Inensive Care Unit at the Guadalupe Victoria Maternity and Child Hospital of Atizapan de Zaragoza since 5 years ago . Previously she was Chief in charge in NICU at Star Médica Luna Parc Cuautitlan Izcalli , where he continues his private practice. Instructor Neonatal CPR , member from ANEM , APROLAM She has published articles in international Journals, and have participation like speaker in diferents international conferences.
Abstract:
As you know in recent years there has been an increase in the critically ill newborns’ survival, thanks to advances in the Neonatology, bringing with it, the development of multiple pathologies, with the consequent increase in the risk of presenting perinatal infections, specially in the group corresponding to prematurity, the incidence and severity of infections in the newborn being well documented, which is largely due to immaturity in both the cellular and humoral response. Reporting a limited functional capacity of all components, in addition to observing quantitative and qualitative deficiencies in the immune system´s cellular components so it is important to develop safe strategies such as supplementation with micronutrients, which allow improving the immune response in the body, of these children. Two decades ago, it was documented that Vitamin D3 in addition to having a regulatory function in the homeostasis of calcium and phosphorus has a relevant role in the modulation of the immune response, Its action is exerted through the union with its nuclear receptor and intervenes activating transcription factors The Receptor is present in cells of different tissues and of the immune system, such as dendritic cells, macrophages and T lymphocytes.
Title: Covid 19- Sustainable healthcare& laboratory infrastructures - Consortium Climate & Health & Prevention
Biography:
Dr. Ivana Haluskova Balter is a Medical and scientific consultancy and advocacy for partnership PPP – ONE Health & ONE Planet, France
Abstract:
Bacteria, viruses, parasites and fungi that are resistant to drug cause 700,000 death each year. By 2050 superbugs inured to treatments could cause up to 10 million deaths annually and costs the global economy US$100 trillion. AMR (antimicrobial) resistance is regarded given Covid -19 lesson again nowadays as a major threat to global public health. Pandemics brought to our attention use of antibiotics given ARDS, hospitalization, hospital acquired pneumonia and ventilator associated pneumonia where particularly in gram negative resistance to last line treatment observed thus framing health as a “global security issue”. as recent example previously Ebola, MERS,SRAS.Cancer and diabetic (association with tuberculosis is known given immune lowered capacities in diabetic patients) given their “at risk “ groups and hospital frontline workers are most exposed to virus with high transmissibility and several approaches – plasma, treatment and vaccines under evaluation and review of regulatory bodies with several pending question given time from signal to action.
